On May 27, 2025, PUMCH and HKSH (Hong Kong Sanatorium & Hospital) signed a strategic collaboration agreement. Under this agreement, both institutions will deepen collaboration in clinical practice, medical education, scientific research, and hospital manag...

From May 26-28, 2025, the Hong Kong Hospital Authority Convention was held at the Hong Kong Convention and Exhibition Centre. Mr. Cao Xuetao, Vice Minister of the National Health Commission, attended the opening ceremony. At the invitation of the Hong Kong Hos...

On May 15, 2025, velaglucerase beta for injection (CAN103), an innovative therapeutic drug for Gaucher disease developed through Phase I/II clinical trials led by PUMCH, received marketing approval from the National Medical Products Administration (NMPA) of Ch...

Recently, a genomic study on anti-MDA5 antibody-positive dermatomyositis completed through collaboration between the Department of Rheumatology at PUMCH (led by Director Li Mengtao and Deputy Director Wang Qian) and the Second Affiliated Hospital of Nanchang U...